Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 14%
Hold 0%
Sell 14%
Strong Sell 0%

Bulls say

Sionna Therapeutics Inc. is well-positioned to address the significant unmet medical needs in the cystic fibrosis treatment market, as median survival for patients remains lower than that of the general population, indicating substantial opportunities for impactful interventions. The company has demonstrated strong calibration of its CF human bronchial epithelial (HBE) assay against the recognized industry standard, enhancing confidence in its product pipeline, especially with ongoing efforts to improve key indicators such as forced expiratory volume (FEV1) and sweat chloride levels. Furthermore, historical data suggesting that improved CFTR function correlates with better lung function underscores the potential efficacy of Sionna's therapeutic candidates in this competitive landscape, warranting a favorable outlook on the company’s future.

Bears say

Sionna Therapeutics Inc faces significant risks that contribute to a negative outlook, including safety signals that may hinder regulatory and commercial viability for its lead candidates, '719 and '451, as well as potential setbacks across its pipeline. The company operates in a high-stakes environment where the probability of success is diminished when targeting novel biology, compounded by clinical, regulatory, and commercial risks, which collectively threaten the potential to secure marketing approvals and compete effectively in the cystic fibrosis market. Furthermore, the reliance on a discounted cash flow model without terminal value suggests an underlying acknowledgment of substantial uncertainties related to future revenue generation and the overall financial health of the company.

SION has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 7 analysts, SION has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.